April 2020 - Buhlmann Diagnostics Corp

Month: April 2020

External Quality Assessment Scheme for Basophil Activation Test

We are pleased to inform you that the first External Quality Assessment (EQA) Scheme for Basophil Activation Test (BAT) is now available.

Continue Reading

Use of basophil activation in oral immunotherapy

An outstanding research paper was published in the top rated Journal of Allergen and Clinical Immunology which evaluated the performance of basophil activation as a biomarker in monitoring clinical efficacy of oral peanut immunotherapy in a clinical trial.

Continue Reading

CALEX Cap Promotion

BÜHLMANN fCAL® turbo + CALEX® Cap (K191718): FDA 510(k) cleared. For in vitro Diagnostic Use. Health Canada License: 98839 CALEX® Cap CALEX® Cap is an FDA 510(k) cleared fecal extraction device for use with BÜHLMANN fCAL® turbo that provides excellent correlation to the traditional manual weighing method and offers efficient, convenient and hygienic extraction of stool samples. Its unique design
Continue Reading

Protected: Historical Overview of Ganglioside Antibodies

There is no excerpt because this is a protected post.

Continue Reading

LabSense News Q1 2020 Edition

In this "Q1 2020 Edition"of BUHLMANN's LabSense News, we are proud to introduce Quantum Blue® Anti-Infliximab (RUO) and Anti-Adalimumab (RUO) to the TDM rapid test portfolio. Check out a new video for Flow CAST® basophil activation test (BAT), view recent BÜHLMANN assay citations, and read an interesting white paper for our BÜHLMANN GanglioCombi® MAG ELISA. 
Continue Reading